investing

6 Stocks to Sell Now

If you own any of these names, this might be a good time to lighten up your positions.

Stock market volatility—especially downward volatility—is back. In seven trading sessions from April 3 through April 11, the Dow Jones industrial average experienced four single-day triple-digit drops, including one of 267 points, as well as one day with a gain of 181 points. For all the wild swings, however, the bull market remains in force. The broader Standard & Poor’s 500-stock index, which has returned 211% since bottoming on March 9, 2009, is off a mere 0.5% from its record high.

Still, the market’s shaky performance raises the question of whether this is a good time to take some profits. In that spirit, we’ve identified six stocks that we think are no longer the bargains they once were or whose growth prospects have become less rosy. If they’re in your portfolio, think about cutting them loose. (The stocks are listed alphabetically; prices are as of May 2.)

Garmin (GRMN, $57.53). Smart phones are eating into the sales of makers of global positioning systems, or GPS. Case in point: Revenues at Garmin’s auto division fell 13% last year. The Switzerland-based company is starting to diversify into areas such as fitness and aviation, which helped boost the stock 74% over the past year. But analysts don’t expect profits to grow meaningfully again before 2015. And the stock is not particularly cheap, selling at 21 times estimated 2014 earnings.

Lululemon Athletica (LULU, $45.45). The Canada-based athletic apparel maker stumbled last year when shoppers complained that the store’s pricey yoga pants were see-through. Lululemon is making amends, but other companies have since entered the high-end athletic apparel market. The stock’s glamour days—it rose 13-fold from early 2009 to last June—are history. Analysts expect same-store sales—sales at stores open for at least one year—to rise only by low-to-mid-single-digit percentages in the current fiscal year, which ends in January.

Netflix (NFLX, $340.65). Shares of the online video-streaming company quadrupled in 2013. But Netflix is feeling the pressure from competitors. The Los Gatos, Cal., company plans to spend about $3 billion to acquire content this year, more than twice Netflix’s cash balance. That means the company will need to raise funds. What’s more, with a price-earnings ratio of 81, based on estimated 2014 earnings, the stock is vulnerable to any sort of disappointing news. Indeed, when word broke in March that Apple and cable TV giant Comcast could offer a joint video-streaming service, Netflix’s stock fell 6.7% in a single day.

RadioShack (RSH, $1.35). The consumer-electronics chain repeatedly fell short of analysts’ earnings estimates last year. The Fort Worth, Tex., company is trying to bounce back, but consumer-electronics is an intensely competitive business, especially when it comes to selling mobile phones. In 2013, sales of mobile phones, which account for more than half of Radio Shack’s revenues—declined 10.4% in stores that were in existence for at least one year. So far this year, the stock has declined 48%. Its low-single-digit price suggests that investors think there’s a good chance Radio Shack is heading toward oblivion.

Rite Aid (RAD, $7.87). The nation’s third-largest drugstore chain wowed investors on April 10 when it reported better-than-expected profits for the quarter that ended March 1. What’s more, the Camp Hill, Pa., company projected higher sales and earnings in the current fiscal year, thanks in part to its recent purchase of RediClinic, which operates 30 in-store health clinics in Texas. As a result, the stock surged 8.4% on what was a miserable day for most stocks. But much of the good news may already be baked into the share price. The stock has tripled over the past year and now trades for 20 times estimated year-ahead earnings. By contrast, Rite Aid’s main rivals, CVS Caremark and Walgreens, trade at 17 and 19 times estimated year-ahead profits, respectively. Rite Aid also carries much more debt than other drugstore chains. That could come back to haunt the company if its turnaround stumbles.

Tesla Motors (TSLA, $210.91). Despite a recent pullback, Tesla’s stock has nearly quintupled over the past year and trades at 120 times estimated 2014 earnings. But the Palo Alto, Cal., company, which went public in 2010, may not be able to keep up with investor expectations. A report by UBS says the rich share price assumes that Tesla will produce one million vehicles per year a decade from now, a daunting task. Meanwhile, Tesla needs to reduce the cost of its car batteries in order to roll out lower-priced models. “The downside is material,” UBS says..

Most Popular

3 Dated Rules of Thumb Retirees Should Think Twice About
investing

3 Dated Rules of Thumb Retirees Should Think Twice About

The tried-and-true investing and saving rules of thumb retirees depend on may no longer be as reliable as they hoped. Don’t let dated “rules” steer yo…
August 11, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
Are You Rich?
personal finance

Are You Rich?

You might be surprised. It depends on how you measure it, and the bar is changing.
August 12, 2022

Recommended

3 Dated Rules of Thumb Retirees Should Think Twice About
investing

3 Dated Rules of Thumb Retirees Should Think Twice About

The tried-and-true investing and saving rules of thumb retirees depend on may no longer be as reliable as they hoped. Don’t let dated “rules” steer yo…
August 11, 2022
The Good News About Recessions for Investors
investing

The Good News About Recessions for Investors

Yes, an official recession is possible, but based on previous recessions, there could be reasons for investors to smile. With that in mind, here are t…
August 11, 2022
Has Inflation Peaked? Here's What the Experts Are Saying
investing

Has Inflation Peaked? Here's What the Experts Are Saying

Inflation decelerated by more than expected in July, but that doesn't mean our era of fast-rising prices – or Fed rate hikes – is over.
August 10, 2022
IRA Bill a Blessing in Disguise for Drug Stocks?
investing

IRA Bill a Blessing in Disguise for Drug Stocks?

Coming limits on drug pricing may not be bad news for drug makers after all.
August 10, 2022